These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8123970)

  • 1. Does ciprofloxacin interact with cyclosporine?
    Hoey LL; Lake KD
    Ann Pharmacother; 1994 Jan; 28(1):93-6. PubMed ID: 8123970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of potential interaction of ciprofloxacin with cyclosporine in bone marrow transplant recipients.
    Krüger HU; Schuler U; Proksch B; Göbel M; Ehninger G
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1048-52. PubMed ID: 2203301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year.
    Benigni A; Bruzzi I; Mister M; Azzollini N; Gaspari F; Perico N; Gotti E; Bertani T; Remuzzi G
    Kidney Int; 1999 Feb; 55(2):674-85. PubMed ID: 9987092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporine (cyclosporin A) pharmacokinetics in renal transplant patients receiving ciprofloxacin.
    Lang J; Finaz de Villaine J; Garraffo R; Touraine JL
    Am J Med; 1989 Nov; 87(5A):82S-85S. PubMed ID: 2589391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ciprofloxacin, but not levofloxacin, affects cyclosporine blood levels in a patient with pure red blood cell aplasia.
    Borrás-Blasco J; Conesa-García V; Navarro-Ruiz A; Marín-Jiménez F; González-Delgado M; Gomez-Corrons A
    Am J Med Sci; 2005 Sep; 330(3):144-6. PubMed ID: 16174999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of drug interactions with cyclosporine.
    Lake KD
    Pharmacotherapy; 1991; 11(5):110S-118S. PubMed ID: 1745616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine nephrotoxicity: associated allograft dysfunction at low trough concentration.
    Jankauskiene A; Druskis V; Laurinavicius A
    Clin Nephrol; 2001 Dec; 56(6):S27-9. PubMed ID: 11770808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diclofenac combined with cyclosporine in treatment refractory rheumatoid arthritis: longitudinal safety assessment and evidence of a pharmacokinetic/dynamic interaction.
    Kovarik JM; Kurki P; Mueller E; Guerret M; Markert E; Alten R; Zeidler H; Genth-Stolzenburg S
    J Rheumatol; 1996 Dec; 23(12):2033-8. PubMed ID: 8970037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature.
    Hootkins R; Fenves AZ; Stephens MK
    Clin Nephrol; 1989 Aug; 32(2):75-8. PubMed ID: 2670382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporine neurotoxicity.
    Hauben M
    Pharmacotherapy; 1996; 16(4):576-83. PubMed ID: 8840363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fulminant hepatic failure possibly related to ciprofloxacin.
    Grassmick BK; Lehr VT; Sundareson AS
    Ann Pharmacother; 1992 May; 26(5):636-9. PubMed ID: 1591420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ciprofloxacin-induced psychosis.
    Reeves RR
    Ann Pharmacother; 1992; 26(7-8):930-1. PubMed ID: 1504404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphology of cyclosporine nephrotoxicity and acute rejection in patients immunosuppressed with cyclosporine and prednisone.
    Sibley RK; Rynasiewicz J; Ferguson RM; Fryd D; Sutherland DE; Simmons RL; Najarian JS
    Surgery; 1983 Aug; 94(2):225-34. PubMed ID: 6348988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a therapeutic or pharmacokinetic rationale for amphotericin B dosing in systemic Candida infections?
    Nagata MP; Gentry CA; Hampton EM
    Ann Pharmacother; 1996; 30(7-8):811-8. PubMed ID: 8826566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics.
    Song J; Kim MG; Choi B; Han NY; Yun HY; Yoon JH; Oh JM
    Ann Pharmacother; 2012 Sep; 46(9):1141-51. PubMed ID: 22947591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation.
    Rodrigo E; Ruiz JC; Angeles de Cos M; Ruiz J; Gago M; Piñera C; Sánchez B; González-Cotorruelo J; Gómez-Alamillo C; Arias M
    Transplant Proc; 2009; 41(6):2328-31. PubMed ID: 19715910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of changing from cyclosporine C0 to C2 monitoring in stable recipients following renal transplantation: a prospective cohort study.
    Zhang Y; Zhang XD; Wang Y
    Transplant Proc; 2011 Dec; 43(10):3697-701. PubMed ID: 22172829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ciprofloxacin-induced nephrotoxicity in patients with cancer.
    Lo WK; Rolston KV; Rubenstein EB; Bodey GP
    Arch Intern Med; 1993 May; 153(10):1258-62. PubMed ID: 8494478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine nephrotoxicity and early posttransplant hyperkalemia in living-donor renal recipients: report of 4 cases.
    Pavleska-Kuzmanovska S; Popov Z; Ivanovski O; Ristovska V; Masin-Spasovska J; Rambabova-Busljetic I; Ivanovski N
    Exp Clin Transplant; 2014 Oct; 12(5):479-83. PubMed ID: 24417207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.